The FDA has approved ensartinib for the treatment of ALK-positive locally advanced or metastatic non-small cell lung cancer in adults who have not received an ALK inhibitor. The approval was based on the eXalt3 trial, which showed ensartinib patients had longer progression-free survival compared to those receiving crizotinib, the current standard of care. Findings also showed a 2-year overall survival rate of 78% in both groups. Common side effects of ensartinib include rash, musculoskeletal pain, and constipation. The recommended dose is 225 mg orally once daily. Ensartinib is a new first-line treatment option for ALK-positive NSCLC patients.
Source link
FDA Approves Ensartinib for ALK+ Advanced NSCLC
